PolarityTE Inc Receives a Buy from Cantor Fitzgerald

By Carrie Williams

Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on PolarityTE Inc (NASDAQ: COOL) on June 12 and set a price target of $65. The company’s shares closed yesterday at $27.16.

Piros wrote:

“: We are reiterating our Overweight rating and lowering our PT to $65 from $70 on City facilities and the company’s recent financing. In addition to exploring the facility, management reviewed the commercial progress for SkinTE and the development pipeline. Following a recent financing in June, Polarity looks well-positioned to deliver on its objectives over the next 24 months, which we describe in this note. We provide a model update to account for the recent raise.”

According to TipRanks.com, Piros is a 1-star analyst with an average return of -1.3% and a 51.1% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Global Blood Therapeutics.

PolarityTE Inc has an analyst consensus of Moderate Buy, with a price target consensus of $65.

See today’s analyst top recommended stocks >>

Based on PolarityTE Inc’s latest earnings release for the quarter ending January 31, the company reported a quarterly GAAP net loss of $14.09 million. In comparison, last year the company had a GAAP net loss of $110 million.

Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of COOL in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

PolarityTE, Inc. engages in the regenerative medicine and tissue engineering platform. The firm seeks to develop and obtain regulatory approval for technology that will utilize a patient’s own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves.